As of 2024-12-12, the EV/EBITDA ratio of Foghorn Therapeutics Inc. (FHTX) is -3.01. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FHTX's latest enterprise value is 285.87 mil USD. FHTX's TTM EBITDA according to its financial statements is -95.09 mil USD. Dividing these 2 quantities gives us the above FHTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.4x | 16.0x |
| Forward P/E multiples | 15.7x - 21.4x | 15.8x |
| Fair Price | (25.89) - (28.69) | (26.16) |
| Upside | -518.9% - -564.3% | -523.3% |
| Date | EV/EBITDA |
| 2024-12-10 | -3.04 |
| 2024-12-09 | -3.15 |
| 2024-12-06 | -3.19 |
| 2024-12-05 | -3.20 |
| 2024-12-04 | -3.75 |
| 2024-12-03 | -3.86 |
| 2024-12-02 | -4.12 |
| 2024-11-29 | -4.05 |
| 2024-11-27 | -3.96 |
| 2024-11-26 | -3.79 |
| 2024-11-25 | -4.13 |
| 2024-11-22 | -4.03 |
| 2024-11-21 | -3.91 |
| 2024-11-20 | -3.99 |
| 2024-11-19 | -4.03 |
| 2024-11-18 | -3.77 |
| 2024-11-15 | -4.05 |
| 2024-11-14 | -4.54 |
| 2024-11-13 | -4.57 |
| 2024-11-12 | -4.55 |
| 2024-11-11 | -4.81 |
| 2024-11-08 | -4.88 |
| 2024-11-07 | -4.78 |
| 2024-11-06 | -4.82 |
| 2024-11-05 | -4.61 |
| 2024-11-04 | -4.22 |
| 2024-11-01 | -4.25 |
| 2024-10-31 | -3.85 |
| 2024-10-30 | -4.19 |
| 2024-10-29 | -4.17 |
| 2024-10-28 | -4.13 |
| 2024-10-25 | -4.08 |
| 2024-10-24 | -3.86 |
| 2024-10-23 | -3.85 |
| 2024-10-22 | -3.76 |
| 2024-10-21 | -3.60 |
| 2024-10-18 | -3.87 |
| 2024-10-17 | -3.92 |
| 2024-10-16 | -4.08 |
| 2024-10-15 | -3.91 |
| 2024-10-14 | -3.74 |
| 2024-10-11 | -3.77 |
| 2024-10-10 | -3.52 |
| 2024-10-09 | -3.64 |
| 2024-10-08 | -3.88 |
| 2024-10-07 | -3.92 |
| 2024-10-04 | -4.07 |
| 2024-10-03 | -3.67 |
| 2024-10-02 | -4.15 |
| 2024-10-01 | -4.46 |